Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. (NYSE: STXS) is active in surgical robotics and medical device innovation, and its news flow reflects ongoing developments in minimally invasive endovascular intervention and cardiac electrophysiology. Company announcements frequently highlight regulatory milestones, product clearances, clinical adoption, and capital markets activity, making the STXS news page a focused resource for tracking these events in one place.
Recent news releases describe U.S. Food and Drug Administration approval of the MAGiC Magnetic Interventional Ablation Catheter, FDA 510(k) clearance for the GenesisX Robotic Magnetic Navigation system, and CE Mark in Europe for the Synchrony digital cath lab system along with a 510(k) submission to the FDA. Other updates cover the commercial launch and first procedures using the MAGiC Sweep high-density electrophysiology mapping catheter, as well as clinical use of the Genesis system at leading medical centers.
Investors and clinicians following STXS can also find news on collaborations, such as the agreement with CardioFocus to advance a robotic pulsed field ablation solution for cardiac arrhythmias. Financial and investor-relations updates, including quarterly earnings press releases and participation in healthcare and growth conferences, are regularly communicated through company news.
This page aggregates these categories of information—regulatory clearances, product launches, clinical milestones, collaborations, and financial communications—so readers can monitor how Stereotaxis’ robotic systems, catheters, and digital cath lab technologies progress over time. For anyone tracking STXS stock or the evolution of its technology portfolio, the news feed offers a structured view of the company’s publicly reported developments.
Stereotaxis (NYSE: STXS) announced U.S. FDA 510(k) clearance for its new robotic system, GenesisX, on November 10, 2025. GenesisX preserves Robotic Magnetic Navigation while improving accessibility through built-in magnetic shielding, operation on standard 120/230V power, no structural anchoring, and an 80% smaller system cabinet, enabling installation in existing non-modified cath labs.
Stereotaxis has started a limited launch in the United States and Europe, is expanding compatible catheters and imaging compatibility, and is preparing supply chain, manufacturing, installation, and commercial processes for a full launch. GenesisX offers flexible capital models including sales, leases, and pay-per-use.
Stereotaxis (NYSE: STXS) will report its third quarter 2025 financial results on Tuesday, November 11, 2025 after the U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) the same day to discuss results and corporate developments. Participants may dial 800-715-9871 (US/Canada) or 646-307-1963 (international) using pass code 4402192. A live and replay webcast will be available via the company’s investor relations website, and a phone replay will be available for one month beginning about four hours after the call.
Stereotaxis (NYSE: STXS) announced on Oct 15, 2025 that it obtained CE Mark in Europe and submitted a 510(k) application to the FDA for the Synchrony system, a platform designed to modernize interventional cath labs. Synchrony pairs a 55" 4K display with 1 frameSynX, a cloud app that the company says is HIPAA and GDPR compliant for remote connectivity, collaboration, recording, and monitoring. The company positions the platforms as foundational for future AI, remote procedures, and improved lab workflows.
Stereotaxis (NYSE: STXS) and CardioFocus announced a Collaboration Agreement on October 13, 2025 to advance a first‑ever robotic Pulsed Field Ablation (PFA) solution toward commercialization.
The collaboration pairs CardioFocus’ CE‑marked Centauri PFA system (used in >9,000 patients and reported in >40 publications) with Stereotaxis’ MAGiC catheter and Robotic Magnetic Navigation (RMN) platform (used in >150,000 patients and reported in >500 publications). Companies completed bench and pivotal preclinical studies showing safe, efficient, deep durable ventricular lesions and plan to move toward first‑human use, clinical trial initiation, regulatory compatibility work, and commercialization in the coming months.
Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, announced that Erasmus Medical Center in Rotterdam has successfully performed its first procedures using the Genesis Robotic Magnetic Navigation System. Erasmus MC, having completed over 4,500 procedures with Stereotaxis technology, becomes the first center in The Netherlands to implement this advanced system.
The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through cardiac ablation. Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center, highlighted the system's enhanced speed and responsiveness, particularly when combined with the MAGiC Catheter, benefiting patients with complex arrhythmias, including children and those with congenital heart disease.
Stereotaxis (NYSE: STXS) has achieved a significant milestone with the completion of the world's first procedures using MAGiC Sweep™, their pioneering robotically-navigated high-density electrophysiology mapping catheter. The procedures were successfully performed at Deborah Heart and Lung Center in New Jersey.
The MAGiC Sweep catheter demonstrated key advantages including accurate mapping of complex anatomy, stable cardiac tissue contact, clear electrogram signals, and absence of ventricular ectopy. Following recent FDA clearance, Stereotaxis has begun the commercial launch in the United States, while European regulatory clearance is pending.
This breakthrough represents a major advancement in robotic electrophysiology, with the technology already used to treat over 150,000 patients globally across the United States, Europe, and Asia.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences in New York City this September. CEO David Fischel will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th, 2025, at 8:00 am EDT, and attend the Lake Street Capital 9th Annual Best Ideas Growth Conference on September 11th, 2025.
The company, which has treated over 150,000 patients globally with its robotic technology, will discuss its technological and commercial progress in its growth strategy. One-on-one meetings with Mr. Fischel can be arranged through conference registration.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will showcase its technology at the upcoming HRX digital health conference from September 4-6, 2025, in Atlanta.
CEO David Fischel will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Following this, at 4:45 PM EDT, a panel of electrophysiologists will lead a session titled "Cutting-Edge Ablation Techniques That Challenge Traditional Methods and Improve Patient Outcomes", exploring robotics, AR/VR, AI, and automation in cardiac care.
The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, reported its Q2 2025 financial results with significant growth. Total revenue reached $8.8 million, up 95% year-over-year and 18% sequentially. System revenue was $3.0 million, while recurring revenue grew 35% to $5.8 million.
The company achieved a notable milestone with FDA clearance of MAGiC Sweep, its first interventional catheter approval in nearly 20 years. Gross margin was 52%, with recurring revenue margin at 68% and system margin at 22%. The quarter ended with $7.0 million in cash, subsequently strengthened by a $12.5 million strategic financing in July.
Management reiterated expectations of double-digit revenue growth for 2025, projecting $2-3 million quarterly system revenue and recurring revenue scaling to $7 million by Q4 2025.
Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, has received FDA 510(k) clearance for its MAGiC Sweep™ catheter, the world's first robotically navigated high-density electrophysiology mapping catheter. The innovative device features 20 electrodes for detailed cardiac mapping and integrates with Stereotaxis' Robotic Systems.
The MAGiC Sweep catheter offers significant advantages including efficient high-density mapping, extended reach and precision, atraumatic design, and improved anatomical accuracy. This marks Stereotaxis' first FDA clearance for an interventional catheter in nearly 20 years and represents a crucial milestone in the company's comprehensive innovation strategy for advancing robotics in electrophysiology.